END 7-OH Act

Summary

Adds 7‑hydroxymitragynine (including synthetic equivalents) to the federal Schedule I list while explicitly excluding 7‑hydroxymitragynine that is naturally present in the kratom plant (Mitragyna speciosa). The change makes synthetic or non‑plant 7‑hydroxymitragynine subject to the strict controls and prohibitions that apply to Schedule I substances, while leaving naturally occurring kratom intact under this provision. This is a narrow statutory change to the Controlled Substances Act that affects how federal law treats isolated or synthetic forms of 7‑hydroxymitragynine — with likely effects on enforcement, manufacturing, distribution, and federally regulated research — and creates a legal distinction between plant material and extracted/synthetic compounds.

• Adds 7‑hydroxymitragynine and synthetic equivalents to Schedule I of the Controlled Substances Act.
• Specifically excludes 7‑hydroxymitragynine that is naturally contained in the kratom plant (Mitragyna speciosa).
• Makes synthetic or extracted 7‑hydroxymitragynine subject to the strict controls and prohibitions of Schedule I.
• Does not schedule whole kratom plant material under this provision.
• Imposes likely increased restrictions on manufacture, distribution, possession, and federally regulated research involving the scheduled compound.
• Includes no funding, effective date, or implementation instructions.
• Creates potential enforcement and regulatory complexity in distinguishing natural plant material from extracts or synthetic forms.
• Is a targeted, single‑issue change to federal drug scheduling rather than a broader policy package.